EICHORCondition: Multiple Sclerosis · Sponsor: Hoffmann-La Roche
The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Profound Research, LLC | Carlsbad, California, United States | — |
| Advanced Neurology of Colorado, LLC | Fort Collins, Colorado, United States | — |
| Neurology Associates PA | Maitland, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Johns Hopkins University School Of Medicine | Baltimore, Maryland, United States | — |
| University of Massachusetts Medical School | Worcester, Massachusetts, United States | — |
| SUNY Upstate Medical University | Syracuse, New York, United States | — |
| Hope Neurology | Knoxville, Tennessee, United States | — |
| Swedish Medical Center | Seattle, Washington, United States | — |
| Centro de Especialidades Neurológicas y Rehabilitación - CENyR | CABA, Buenos Aires, Argentina | — |
| Focus CECIC | CABA, CABA / Buenos Aires, Argentina | — |
| INECO Neurociencias Orono | Rosario, Santa Fe Province, Argentina | — |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07074886